Floatz logo

Semaglutide

Intracranial Hypertension

Explore 2 assets in Intracranial Hypertension →
Floatz Rating
BB69/100
Confidence
Indicative
v0.2
Sponsor
Rigmor Højland Jensen
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Intracranial Hypertension

AssetSponsorPhaseRating
Semaglutide (this asset)Rigmor Højland JensenApprovedBB · 69
ApsololTanta UniversityP3B
MannitolBeth Israel Deaconess Medical CenterP3B

Other indications for Semaglutide

IndicationSponsorPhaseRating
Metabolic Disease—P4A · 81
Polycystic Ovary Syndrome—P4BBB · 79
Type 2 Diabetes Mellitus—P4BBB · 78

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Semaglutide in Intracranial Hypertension. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/semaglutide-intracranial-hypertension

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →